Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial - Colombel, Jean-Frederic; Panaccione, Remo; Bossuyt, Peter; Lukas, Milan; Baert, Filip; Vaňásek, Tomas; Danalioglu, Ahmet; Novacek, Gottfried; Armuzzi, Alessandro; Hébuterne, Xavier; Travis, Simon; Danese, Silvio; et al. (The Lancet (British edition), 2017)
Keywords: Abscesses; Adalimumab - therapeutic use; Adolescent; Adult; Aged; Algorithms; Antirheumatic Agents - therapeutic use; Arthralgia; Azathioprine; Azathioprine - therapeutic use; Biological products; Biomarkers; C-reactive protein; C-Reactive Protein - immunology; Clinical trials; Control algorithms; Control theory; Corticoids; Corticosteroids; Crohn Disease - drug therapy; Crohn Disease - immunology; Crohn's Disease; Decisions; Disease control; Disease Management; Drug therapy; Drug Therapy, Combination; Endoscopy; Evidence-based medicine; Female; Fistula; Gastrointestinal tract; Glucocorticoids - therapeutic use; Headache; Health services; Humans; Immunomodulation; Immunomodulators; Induction therapy; Inflammation; Intestine; Male; Management; Middle Aged; Monitoring; Monoclonal antibodies; Mucosa; Nausea; Patient safety; Patients; Prednisone; Prednisone - therapeutic use; Proteins; Randomization; Remission Induction; Rhinopharyngitis; Severity of Illness Index; Signs and symptoms; Surgery; Telemedicine; Treatment Outcome; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; Ulcers; Young Adult; Belgium